Advertisement
Australia markets closed
  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     
  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     
  • AUD/USD

    0.6691
    +0.0011 (+0.17%)
     
  • OIL

    80.02
    +0.79 (+1.00%)
     
  • GOLD

    2,419.30
    +33.80 (+1.42%)
     
  • Bitcoin AUD

    99,461.22
    +2,355.88 (+2.43%)
     
  • CMC Crypto 200

    1,358.71
    -15.13 (-1.10%)
     
  • AUD/EUR

    0.6152
    +0.0013 (+0.21%)
     
  • AUD/NZD

    1.0907
    +0.0001 (+0.01%)
     
  • NZX 50

    11,699.79
    -28.27 (-0.24%)
     
  • NASDAQ

    18,471.65
    -86.32 (-0.47%)
     
  • FTSE

    8,420.26
    -18.39 (-0.22%)
     
  • Dow Jones

    39,869.40
    +0.02 (+0.00%)
     
  • DAX

    18,704.42
    -34.39 (-0.18%)
     
  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     
  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure helps cut through all the noise.

Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.

2 Stocks to Add to Your Watchlist

The Zacks Earnings ESP, or Expected Surprise Prediction, aims to find earnings surprises by focusing on the most recent analyst revisions. The basic premise is that if an analyst reevaluates their earnings estimate ahead of an earnings release, it means they likely have new information that could possibly be more accurate. The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction.

ADVERTISEMENT

The final step today is to look at a stock that meets our ESP qualifications. Moderna (MRNA) earns a Zacks Rank #3 two days from its next quarterly earnings release on May 2, 2024, and its Most Accurate Estimate comes in at -$3.55 a share.

By taking the percentage difference between the -$3.55 Most Accurate Estimate and the -$3.59 Zacks Consensus Estimate, Moderna has an Earnings ESP of 0.99%.

MRNA is one of just a large database of Medical stocks with positive ESPs. Another solid-looking stock is Edwards Lifesciences (EW).

Edwards Lifesciences, which is readying to report earnings on July 24, 2024, sits at a Zacks Rank #3 (Hold) right now. It's Most Accurate Estimate is currently $0.70 a share, and EW is 85 days out from its next earnings report.

For Edwards Lifesciences, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $0.70 is 0.25%.

MRNA and EW's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.

Find Stocks to Buy or Sell Before They're Reported

Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Moderna, Inc. (MRNA) : Free Stock Analysis Report

Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research